259 related articles for article (PubMed ID: 18516762)
1. Targeted therapies in Waldenström macroglobulinemia.
Burwick N; Roccaro AM; Leleu X; Ghobrial IM
Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
[TBL] [Abstract][Full Text] [Related]
2. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
[TBL] [Abstract][Full Text] [Related]
3. How we treat Waldenström's macroglobulinemia.
Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
[TBL] [Abstract][Full Text] [Related]
4. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
7. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
8. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
10. Current treatment options for Waldenström macroglobulinemia.
Vijay A; Gertz MA
Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
12. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
[TBL] [Abstract][Full Text] [Related]
13. Waldenstrom macroglobulinemia.
Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
15. [Waldemström s macroglobulinemia].
Khosravi Shahi P; del Castillo Rueda A; Díaz Muñoz de la Espada VM
An Med Interna; 2006 Jun; 23(6):291-3. PubMed ID: 17067225
[TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
[TBL] [Abstract][Full Text] [Related]
17. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
18. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
Treon SP; Hunter ZR; Matous J; Joyce RM; Mannion B; Advani R; Cook D; Songer J; Hill J; Kaden BR; Sharon D; Steiss R; Leleu X; Branagan AR; Badros A
Clin Cancer Res; 2007 Jun; 13(11):3320-5. PubMed ID: 17545538
[TBL] [Abstract][Full Text] [Related]
19. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS; Jia X; Patterson CJ; Roccaro AM; Xu L; Sacco A; O'Connor K; Soumerai J; Ngo HT; Hatjiharissi E; Hunter ZR; Ciccarelli B; Manning R; Ghobrial IM; Leleu X; Treon SP
Br J Haematol; 2008 Sep; 142(5):775-85. PubMed ID: 18537966
[TBL] [Abstract][Full Text] [Related]
20. Update on therapeutic options in Waldenström macroglobulinemia.
Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
